Allergy Therapeutics
plc
("Allergy
Therapeutics" or "the Group")
Directorate
Change
Appointment of David Ball as
Non-Executive Director
27
June 2024 Allergy Therapeutics (AIM:
AGY), the fully integrated commercial biotechnology company
specialising in allergy vaccines, today announces that David Ball
will join the Board of Allergy Therapeutics as an independent
Non-Executive Director with immediate effect. David is also
appointed Chair of the Board's Audit and Risk Committee.
David has over 25 years of
experience in financial markets, including 15 years as an equity
portfolio manager and partner with Tudor Investment Corporation.
David is a chartered accountant and holds undergraduate and
postgraduate degrees in engineering from Cambridge
University.
Peter Jensen, Chairman of Allergy Therapeutics,
said: "I am delighted to announce David's appointment and welcome
him to the Board at this exciting and positive time for the
Company. David has an impressive breadth of executive and financial
markets experience, and we look forward to his contributions to the
Board and oversight of our Audit and Risk
Committee."
Commenting on his appointment, David Ball said:
"I am delighted to be joining the Board of Allergy Therapeutics
and look forward to working with my fellow Board members and the
wider team to further develop Allergy's leading position in the
sector."
Additional Information in respect of the AIM
Rules:
David William Dawson Ball, aged 55,
is a director of Argonaute RNA Limited and in the previous five
years, David was a director of Brainomix Limited. David does not
have an interest in ordinary shares in the Company. The Company
confirms that there is no other information in relation to David
Ball's appointment that is required to be disclosed pursuant to
Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
- ENDS -
For
further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and
Broker)
Emma Earl, Will Goode, Freddy
Crossley, Mark Rogers, Corporate Finance
Rupert Dearden, Corporate
Broking
+44 (0)20 7886 2500
ICR
Consilium
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see
www.allergytherapeutics.com.